Nephrotoxic Polypharmacy and Risk of Contrast Medium-Induced Nephropathy in Hospitalized Patients Undergoing Contrast-Enhanced CT
- PMID: 26397318
- DOI: 10.2214/AJR.15.14329
Nephrotoxic Polypharmacy and Risk of Contrast Medium-Induced Nephropathy in Hospitalized Patients Undergoing Contrast-Enhanced CT
Abstract
Objective: For unknown reasons, there is discordance among previous reports with regard to the association of contrast medium (CM) with nephropathy and the incidence of nephropathy after contrast-enhanced CT. This study aimed to determine the frequency of and possible factors related to CM-induced nephropathy in hospitalized patients, with an emphasis on detailing coprescriptions with nephrotoxic potential.
Materials and methods: Of 1378 inpatients who underwent CT, 208 (15.1%) met the inclusion criteria: receipt of IV iodinated CM and baseline serum creatinine level obtained within 45 days before and within 2 weeks after CT. Patient demographics, clinical characteristics, comorbidity, nephrotoxic comedications (nine classes of drugs), and type of CM administered were retrospectively reviewed. Relationships between CM-induced nephropathy (serum creatinine level increase ≥ 25% or ≥ 0.5 mg/dL after CT) and risk factors were assessed by stepwise multivariate logistic regression.
Results: The cohort of 208 subjects had a high number of comorbidities (mean [± SD], 5.8 ± 3.5 diagnoses) and a high rate of receiving nephrotoxic comedications (45.2%). CM-induced nephropathy was detected in 27 (13.0%) patients. Concurrent use of four nephrotoxic agents (odds ratio [OR], 26.250; 95% CI, 3.673-233.993) was the most influential factor associated with CM-induced nephropathy; other predictors included preexisting renal disease (OR, 8.218; 95% CI, 1.622-42.357), baseline serum creatinine level less than 0.7 or greater than or equal to 1.3 mg/dL (OR, 3.463; 95% CI, 1.341-9.025), and hemoglobin level less than 9.3 g/dL (OR, 3.141; 95% CI, 1.087-8.946).
Conclusion: Among the known risk factors, such as preexisting renal disease, high serum creatinine level, and low hemoglobin level, a statistically significant association was identified between CM-induced nephropathy and concurrent receipt of four nephrotoxic medications. Relevant preventive measures are warranted for individuals at risk, especially hospitalized patients receiving multiple nephrotoxic medications who require contrast-enhanced CT.
Keywords: incidence; iodinated contrast medium; nephropathy; renal insufficiency; risk factors.
Similar articles
-
Incidence of contrast material-induced nephropathy after neuroendovascular procedures.Radiology. 2014 Dec;273(3):853-8. doi: 10.1148/radiol.14131104. Epub 2014 Aug 1. Radiology. 2014. PMID: 25102293
-
Incidence of contrast-induced nephropathy in patients with multiple myeloma undergoing contrast-enhanced CT.AJR Am J Roentgenol. 2011 May;196(5):1094-101. doi: 10.2214/AJR.10.5152. AJR Am J Roentgenol. 2011. PMID: 21512075
-
Probability of reduced renal function after contrast-enhanced CT: a model based on serum creatinine level, patient age, and estimated glomerular filtration rate.AJR Am J Roentgenol. 2009 Aug;193(2):494-500. doi: 10.2214/AJR.08.1908. AJR Am J Roentgenol. 2009. PMID: 19620448
-
Recent issues in contrast-induced nephropathy.Int J Urol. 2011 Oct;18(10):686-90. doi: 10.1111/j.1442-2042.2011.02830.x. Epub 2011 Aug 11. Int J Urol. 2011. PMID: 21834851 Review.
-
Is the risk of contrast-induced nephropathy a real contraindication to perform intravenous contrast enhanced Computed Tomography for non-traumatic acute abdomen in Emergency Surgery Department?Acta Biomed. 2018 Dec 17;89(9-S):158-172. doi: 10.23750/abm.v89i9-S.7891. Acta Biomed. 2018. PMID: 30561410 Free PMC article.
Cited by
-
The Advantages and Challenges of Using Real-World Data for Patient Care.Clin Transl Sci. 2020 Jan;13(1):4-7. doi: 10.1111/cts.12683. Epub 2019 Aug 27. Clin Transl Sci. 2020. PMID: 31456349 Free PMC article. No abstract available.
-
Incidence and risk factors of acute kidney injury in patients with polypharmacy: a systematic review and meta-analysis.Int J Clin Pharm. 2025 Aug 29. doi: 10.1007/s11096-025-01988-y. Online ahead of print. Int J Clin Pharm. 2025. PMID: 40880032 Review.
-
Personalized contrast agent dosing to prevent contrast induced nephropathy in high risk populations in Guangdong, China.Sci Rep. 2025 Feb 26;15(1):6938. doi: 10.1038/s41598-025-91986-x. Sci Rep. 2025. PMID: 40011557 Free PMC article.
-
Iodinated contrast medium: Is there a re(n)al problem? A clinical vignette-based review.Crit Care. 2020 Nov 10;24(1):641. doi: 10.1186/s13054-020-03365-9. Crit Care. 2020. PMID: 33168006 Free PMC article. Review.
-
Lean body weight-based contrast injection protocol in liver CT: optimization of contrast medium dose.Radiol Med. 2025 Apr;130(4):486-492. doi: 10.1007/s11547-024-01944-2. Epub 2024 Dec 30. Radiol Med. 2025. PMID: 39738873 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous